Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease

20. September 2026 aktualisiert von: Fatima Yaman, Kutahya Health Sciences University

Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease

This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.

Studienübersicht

Status

Noch keine Rekrutierung

Studientyp

Interventionell

Einschreibung (Geschätzt)

46

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Kütahya, Türkei (türkiye), 43020
        • Kutahya Health Sciences University
        • Kontakt:
        • Hauptermittler:
          • Fatima YAMAN, Assoc. Prof
        • Hauptermittler:
          • Meltem ÇOBAN, Dr.
        • Unterermittler:
          • Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
        • Unterermittler:
          • Mevlüt DEMİR, Assoc. Prof
        • Unterermittler:
          • Cansu OZBAYER, Prof. Dr.
        • Unterermittler:
          • Fatih KAR, Assoc. Prof.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

35 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Stable coronary artery disease
  • History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Referred and considered clinically eligible for a structured cardiac rehabilitation program
  • Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
  • Ability and willingness to participate in the study and complete the cardiac rehabilitation program

Exclusion Criteria:

  • Symptoms or signs of myocardial ischemia
  • Significant left ventricular outflow tract obstruction
  • Ventricular arrhythmia
  • Significant valvular heart disease
  • Uncontrolled hypertension
  • Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
  • Active malignancy
  • Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
  • Body mass index greater than 35 kg/m²
  • History of orthopedic surgery within the previous 6 months
  • Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
  • Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
  • Known psychiatric disorder
  • Presence of a permanent cardiac pacemaker

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Personalized Cardiac Rehabilitation Group

Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.

Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in miRNA Expression Levels
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Peak Oxygen Uptake (VO₂max)
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Exercise Workload
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Six-Minute Walk Test Distance
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Resting Heart Rate
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Heart Rate
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Health-Related Quality of Life
Zeitfenster: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. September 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2026

Studienabschluss (Geschätzt)

1. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

20. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. September 2026

Zuerst gepostet (Tatsächlich)

25. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

20. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren